Sociedad Americana de Hirudoterapia

Identification and Screening of Novel Antimicrobial Peptides from Medicinal Leech via Heterologous Expression in E. coli

Basic science / preclinical published in Int J Mol Sci (2025)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: In vitro / laboratoryFarmacología salivalGenómica y proteómicaDesarrollo de fármacosSeguridad y control de infeccionesSerebrennikova M et al. · International journal of molecular sciences, 2025

Abstract

The growing threat of infectious diseases requires novel therapeutics with different mechanisms of action. Antimicrobial peptides (AMPs), which are crucial for innate immunity, are a promising research area. The medicinal leech (Hirudo medicinalis) is a potential source of bioactive AMPs that are vital while interacting with microorganisms. This study aims to investigate the antimicrobial properties of peptides found in the H. medicinalis genome using a novel high-throughput screening method based on the expression of recombinant AMP genes in Escherichia coli. This approach enables the direct detection of AMP activity within cells, skipping the synthesis and purification steps, while allowing the simultaneous analysis of multiple peptides. The application of this method to the first identified candidate AMPs from H. medicinalis resulted in the discovery of three novel peptides: LBrHM1, NrlHM1 and NrlHM2. These peptides, which belong to the lumbricin and macin families, exhibit significant activity against E. coli. Two fragments of the new LBrHM1 homologue were synthesised and studied: a unique N-terminal fragment (residues 1-23) and a fragment (residues 27-55) coinciding with the active site of lumbricin I. Both fragments exhibited antimicrobial activity in a liquid medium against Bacillus subtilis. Notably, the N-terminal fragment lacks homologues among previously described AMPs.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsEscherichia coliAnimalsAntimicrobial PeptidesHirudo medicinalisAmino Acid SequenceMicrobial Sensitivity TestsAntimicrobial Cationic PeptidesBacillus subtilisRecombinant ProteinsAnti-Bacterial AgentsGene Expression

Resumen

High-throughput screening of candidate AMPs from the Hirudo medicinalis genome using recombinant expression in E. coli. Discovery of three novel AMPs (LBrHM1, NrlHM1, NrlHM2) from lumbricin and macin families, including a unique N-terminal fragment without prior homologues.

Por qué esto importa para la hirudoterapia

This study (Serebrennikova et al., International Journal of Molecular Sciences 2025) applied a high-throughput screening method based on recombinant expression in Escherichia coli to mine the Hirudo medicinalis genome for antimicrobial peptides, discovering three novel peptides (LBrHM1, NrlHM1, NrlHM2) from the lumbricin and macin families with significant activity against E. coli; two synthesized fragments of the LBrHM1 homologue, including a unique N-terminal fragment with no known homologues, showed antimicrobial activity against Bacillus subtilis. For hirudotherapy, this strengthens the medicinal-leech drug-discovery narrative by extending the leech secretome beyond anticoagulants into host-defense antimicrobial peptides, a potential source of new antibacterial leads amid rising antimicrobial resistance. Honest caveat: these are early in-vitro discovery and screening results against laboratory bacteria using recombinant expression, not clinical or even purified-compound therapeutic data, and they do not establish efficacy or safety in any disease setting.

Citación

Identification and Screening of Novel Antimicrobial Peptides from Medicinal Leech via Heterologous Expression in E. coli.

Serebrennikova M et al. · International journal of molecular sciences, 2025

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.